InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（3 笔）
内部人交易记录
董事已披露买入
3
已披露卖出
3
T+90 胜率
33%
T+90 平均收益
-21.0%
基于 3 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the detailed record of transactions filed by Cohen Neil Harris, 董事. Director active across 1 company, notably Chemomab Therapeutics Ltd.. In total, 6 reports have been logged. Split: 3 buys · 3 sells. Total volume traded: €37k. History available since 6 December 2021. The latest transaction was disclosed on 28 August 2026 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Cohen Neil Harris
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
1,000 股@ US$2.800.014% mcap6.5% 占其流量American Depositary SharesSEC:0001178913-26-004371:1
1,304 股@ US$2.850.019% mcap8.6% 占其流量American Depositary SharesSEC:0001178913-26-004371:0
2,409 股@ US$2.0010.4% 占其流量American Depositary SharesSEC:0001178913-22-004100:0
2,000 股@ US$3.1919.3% 占其流量American Depositary SharesSEC:0001178913-22-002093:0
标准退出：2022年8月16日 (T+90)
2,000 股@ US$4.2024.3% 占其流量American Depositary SharesSEC:0001178913-22-001117:0
标准退出：2022年6月12日 (T+90)
2,000 股@ US$7.4341.6% 占其流量American Depositary SharesSEC:0001178913-21-003807:0
标准退出：2022年3月6日 (T+90)
6 条申报中的 6 条
About Cohen Neil Harris
Cohen Neil Harris is Administrateur at Chemomab Therapeutics Ltd. (XNAS). He has 6 filings in total, and across the sampled recent filings, purchases total EUR 26921 and sales total EUR 10240, with transactions ranging from 2021-12-08 to 2026-09-01. The modal transaction nature is Cession.
